CD22-targeted CAR-T cell therapy (PersonGen Biomedicine)

抗CD22嵌合抗原T细胞疗法（博生吉）

Report date: 2024/11/21 20:00:04

Base Information

Drug NameCD22-targeted CAR-T cell therapy (PersonGen Biomedicine)

Drug Alias NameAnti-CD22 CAR T cellsCD22-targeted CAR-T cellsCAR-CD22 cell immunotherapy

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD22

TargetsCD22

Therapy Area/IndicationsNeoplasms, Plasma CellLymphoma, Mantle-CellLymphoma, Follicular +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesPersongen Biotherapeutics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms, Plasma CellLymphoma, Mantle-CellLymphoma, Follicular +[6]

Other Information

ATC CodeN/A